Jan Willem Alffenaar
Overview
Explore the profile of Jan Willem Alffenaar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McMullan B, Kim H, Alastruey-Izquierdo A, Tacconelli E, Dao A, Oladele R, et al.
Med Mycol
. 2024 Jun;
62(6).
PMID: 38935910
This systematic review evaluates the current global impact of invasive infections caused by Pneumocystis jirovecii (principally pneumonia: PJP), and was carried out to inform the World Health Organization Fungal Priority...
2.
Migliori G, Tiberi S, Zumla A, Petersen E, Chakaya J, Wejse C, et al.
Int J Infect Dis
. 2020 Feb;
92S:S15-S25.
PMID: 32032752
The continuous flow of new research articles on MDR-TB diagnosis, treatment, prevention and rehabilitation requires frequent update of existing guidelines. This review is aimed at providing clinicians and public health...
3.
Sotgiu G, Tiberi S, DAmbrosio L, Centis R, Alffenaar J, Caminero J, et al.
Eur Respir J
. 2016 Sep;
48(5):1503-1507.
PMID: 27587544
No abstract available.
4.
Tiberi S, Sotgiu G, DAmbrosio L, Centis R, Arbex M, Alarcon Arrascue E, et al.
Eur Respir J
. 2016 Apr;
47(6):1758-66.
PMID: 27076583
No large study to date has ever evaluated the effectiveness, safety and tolerability of imipenem/clavulanate versus meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of...
5.
Tiberi S, Payen M, Sotgiu G, DAmbrosio L, Alarcon Guizado V, Alffenaar J, et al.
Eur Respir J
. 2016 Mar;
47(4):1235-43.
PMID: 26965290
No large study has ever evaluated the efficacy, safety and tolerability of meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was...
6.
Tiberi S, Sotgiu G, DAmbrosio L, Centis R, Arbex M, Alarcon Arrascue E, et al.
Clin Infect Dis
. 2016 Feb;
62(9):1188-90.
PMID: 26908794
No abstract available.